Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics entered a major financing collaboration with Blackstone Life Sciences built around future sales of its anti‑IL‑13 antibody zumilokibart. Under a new revenue participation right agreement, Apogee receives an upfront $100.0 million now, with the potential for additional tranches of $100.0 million, $200.0 million, and $250.0–$400.0 million tied to Phase 3 enrollment, positive Phase 3 results, and U.S. marketing approval by December 31, 2030.
The revenue share runs for 15 years from first approval, with tiered percentages on annual global zumilokibart sales. For Tier 1 sales up to $5 billion, the maximum combined revenue share can reach 3.4375%, declining at higher sales levels and subject to a $1.0 billion cap on Tranche 4‑related payments. Apogee and Blackstone also agreed to negotiate up to $500.0 million in senior debt.
Combined with Apogee’s existing $1.3 billion cash balance, management highlights up to $1.3 billion in flexible, largely non‑dilutive capital that it believes can support Phase 3 development and potential commercialization of zumilokibart. Following this deal, Apogee withdrew its prior cash runway end‑date guidance.
Apogee Therapeutics entered a major financing collaboration with Blackstone Life Sciences built around future sales of its anti‑IL‑13 antibody zumilokibart. Under a new revenue participation right agreement, Apogee receives an upfront $100.0 million now, with the potential for additional tranches of $100.0 million, $200.0 million, and $250.0–$400.0 million tied to Phase 3 enrollment, positive Phase 3 results, and U.S. marketing approval by December 31, 2030.
The revenue share runs for 15 years from first approval, with tiered percentages on annual global zumilokibart sales. For Tier 1 sales up to $5 billion, the maximum combined revenue share can reach 3.4375%, declining at higher sales levels and subject to a $1.0 billion cap on Tranche 4‑related payments. Apogee and Blackstone also agreed to negotiate up to $500.0 million in senior debt.
Combined with Apogee’s existing $1.3 billion cash balance, management highlights up to $1.3 billion in flexible, largely non‑dilutive capital that it believes can support Phase 3 development and potential commercialization of zumilokibart. Following this deal, Apogee withdrew its prior cash runway end‑date guidance.
Apogee Therapeutics reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The study met all primary and secondary endpoints with high statistical significance, including 65.9% of mid-dose patients achieving EASI-75, a 41.9% placebo-adjusted improvement. Zumilokibart was well tolerated with a safety profile consistent with other drugs in its class. Based on these data and prior Part A maintenance results, Apogee plans to advance the mid-dose into Phase 3 AD trials in the second half of 2026 and has outlined additional trials in asthma and eosinophilic esophagitis. The company also announced a strategic financing collaboration with Blackstone Life Sciences expected to fund development through potential commercialization of zumilokibart in AD, asthma, and EoE.
Apogee Therapeutics reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The study met all primary and secondary endpoints with high statistical significance, including 65.9% of mid-dose patients achieving EASI-75, a 41.9% placebo-adjusted improvement. Zumilokibart was well tolerated with a safety profile consistent with other drugs in its class. Based on these data and prior Part A maintenance results, Apogee plans to advance the mid-dose into Phase 3 AD trials in the second half of 2026 and has outlined additional trials in asthma and eosinophilic esophagitis. The company also announced a strategic financing collaboration with Blackstone Life Sciences expected to fund development through potential commercialization of zumilokibart in AD, asthma, and EoE.
Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of Common Stock in open-market transactions. The sales occurred on May 13, 2026 at weighted average prices of about $82.05 and $82.58 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the sales, Henderson continues to hold over one million Apogee Therapeutics shares, so the transactions represent a small portion of his overall position.
APGE proposed resale of 60,000 shares. The filing lists 60,000 shares of Common Stock to be sold under Rule 144, with a shares-outstanding figure of 75,389,375 as of 05/13/2026. The notice also shows two recent dispositions of 20,000 shares each on 03/11/2026 and 04/08/2026.
Apogee Therapeutics reported a larger quarterly net loss as it continues to invest heavily in its inflammatory and immunology pipeline. For the three months ended March 31, 2026, net loss was $74.1M compared with $55.3M a year earlier, driven by higher research and development and general and administrative expenses.
R&D spending rose to $60.8M from $46.4M, while G&A increased to $22.0M from $16.7M. The company ended the quarter with substantial liquidity, including $451.8M in cash and cash equivalents, $608.1M in marketable securities and $198.4M in long‑term marketable securities, and believes this will fund operations for at least 12 months. Apogee also highlights positive Phase 2 data for its lead antibody zumilokibart in atopic dermatitis, supporting its strategy to develop differentiated biologics across major inflammatory indications.
Apogee Therapeutics reported a larger net loss but strong cash position for the first quarter of 2026 while highlighting significant pipeline progress. Net loss was $74.1 million for the quarter ended March 31, 2026, compared with $55.3 million a year earlier, driven by higher R&D and G&A spending.
R&D expenses rose to $60.8 million from $46.4 million, and G&A expenses increased to $22.0 million from $16.7 million, reflecting expansion of zumilokibart and combination programs and higher personnel costs. Cash, cash equivalents, marketable securities and long‑term marketable securities totaled $1.3 billion as of March 31, 2026, up from $902.9 million on December 31, 2025, supported by an upsized public equity offering with approximately $403 million in gross proceeds.
The company reported strong 52‑week Phase 2 APEX Part A data for zumilokibart in atopic dermatitis, with high maintenance of EASI‑75 and IGA 0/1 responses on 3‑ and 6‑month dosing, and plans to start Phase 3 trials in the second half of 2026. Interim positive Phase 1b asthma results, advancing combination assets APG279 and APG273, and a stated cash runway into 2029 underpin plans to pursue a future BLA filing for zumilokibart in atopic dermatitis.
Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported a mix of stock sales and option exercises. On May 6, 2026, he completed open-market sales totaling 5,500 shares of common stock at weighted average prices of $84.60 and $83.92 per share under a pre-arranged Rule 10b5-1 trading plan.
He also exercised 4,125 stock options at an exercise price of $22.86 per share, converting options into common stock. A related option grant covers 175,345 shares that vest in forty-eight equal monthly installments through December 18, 2027, conditioned on his continued service.
APGE reported an intended sale of 22,000 common shares under Rule 144, comprised of 16,500 shares from exercised stock options and 5,500 shares from restricted stock awards.
The filing also discloses two 10b5-1 sales in the past three months totaling 11,000 shares (5,500 on 2026-04-01 for $466,639.80 and 5,500 on 2026-03-04 for $390,839.05).
Apogee Therapeutics, Inc. Chief Financial Officer Jane Henderson executed pre-planned open-market sales of company common stock. On May 1, 2026, she sold a total of 2,000 shares in three transactions at reported weighted average prices between about $81 and $83 per share, under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these sales, she directly holds 173,371 shares of Apogee common stock.
Insider sales reported under Rule 144 via 10b5-1 plan. The filing lists five separate 10b5-1 dispositions by Jane Henderson of 2,000 shares each on 02/02/2026, 03/02/2026, 03/25/2026, 04/01/2026, and 04/16/2026, with proceeds shown for each trade.